Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody neutralization Antibody titre B.1.1.529 BNT162b2 booster Breakthrough infection convalescent CoronaVac COVID-19 detectable dose elicited geometric GMT Immune escape individual Infection less natural infection neutralization neutralizing antibody Neutralizing antibody response of BNT162b2 omicron Omicron, Neutralization plaque reduction neutralization PRNT reduction relative SARS-CoV-2 susceptible Transmissibility vaccinated individual vaccination Vaccine Vaccines virus viruses VoC wild- type WT virus [DOI] 10.1016/j.jcv.2022.105273 PMC 바로가기
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesArticle Published on 2022-10-292022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Antibody titer CCP collected convalescent plasma COVID-19 Donor dose effective geometric geometric mean titer Immune escape Immunocompromised implication Infection lesson monoclonal antibodies monoclonal antibody mRNA vaccine neutralization neutralize Neutralizing Neutralizing antibody titer omicron Outpatient pandemic plasma plasma activity provide recipients reduction representing SARS-CoV-2 variant sera subject therapeutic Therapies uninfected vaccinee variant variants of concern [DOI] 10.1038/s41467-022-33864-y PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Longitudinal serologic and viral testing post-SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort-Georgia, October 2020‒April 2021Article Published on 2022-10-272022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] administration Antibody detection Antibody Response binding binding antibody blood collection Card Cohort conducted COVID-19 COVID-19 vaccination COVID-19 vaccine Culture detectable dose evaluate evaluated Final first dose geometric IgA antibodies IgA antibody IgG IgG titer IgM antibodies immune response Immunocompromised Infection longitudinal median age mounted mRNA nasal nine nursing home observation participant polymerase chain positive Post-infection Quantitative questionnaire reverse transcription robust RT-PCR SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2-specific immune response serology specimen subsequent vaccination viral culture [DOI] 10.1371/journal.pone.0275718 PMC 바로가기
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy AdultsArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CL acid administration adverse event affected agent Antiviral assessment AUC C max COVID-19 demonstrated dose doses drug-drug interaction Effect ensitrelvir first-in-human Food Intake geometric increase in Infection inhibitor Japanese mild in severity MOST novel oral dosing P450 participant Participants participants with SARS-CoV-2 pharmacokinetics phase 1 study Placebo plasma proportionality protease Protease inhibitor Randomized reduced resolved Safety SARS-CoV-2 selective single dose substrate T max Tolerability Treatment viral replication [DOI] 10.1128/aac.00632-22 PMC 바로가기
Reduced B cell antigenicity of Omicron lowers host serologic responseArticle Published on 2022-10-182022-11-15 Journal: Cell Reports [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Antibody Response Antibody titer antigenicity B cell Breakthrough infection common cold coronavirus computational structural biology conserved CP: Immunology CP: Microbiology cross-reactivity deep learning ELISA Epitopes evade explain feature geometric Host Infection less Lower mechanism Mice immunization experiment mutated Neutralizing omicron Omicron variant of concern RBD RBS Receptor binding Receptor binding domain receptor binding site reduced reduction reduction in reveal SARS-CoV-2 Serologic response serological response serum Spike protein trajectory vaccine-induced antibody variant variants viral evolution [DOI] 10.1016/j.celrep.2022.111512 PMC 바로가기
Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIVArticle Published on 2022-10-172022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI conducted Control COVID-19 COVID-19 vaccine Day decrease determine dropped Effect ELISA enrolled examined extension FIVE geometric geometric mean concentration GMC GMCs humoral humoral immune response IgG IgG antibody inactivated Inactivated COVID-19 vaccine investigated longitudinal longitudinal humoral response NAb Neutralizing Neutralizing antibodies no significant difference peaked People living with HIV (PLWH) PLWH positive SARS-CoV-2 neutralizing antibody Seroconversion seroconversion rate Seven significantly significantly lower specific IgM two group two groups vaccination with HIV [DOI] 10.3389/fimmu.2022.988304 PMC 바로가기
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, PeruArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] 진단, [키워드] administration ANCOVA anti-SARS-CoV-2 IgG antibody BBIBP-CorV BNT162b2 BNT162b2 vaccine booster conducted COVID-19 infection COVID-19 vaccine dose Elderly patient evaluated geometric geometric mean ratio HCW healthcare worker Heterologous heterologous vaccine homologous IgG IgG antibody IgG level immunized immunogenic immunogenicity increase in median mRNA vaccine National of BNT162b2 participant Pfizer produced prospective cohort study reactogenic reactogenicity regimen regressions Safe significantly Sinopharm two group vaccination Vaccine vaccine for COVID-19 was measured [DOI] 10.1371/journal.pone.0268419 PMC 바로가기
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] 치료제, [키워드] 24 hour adjusted Administered adverse event adverse outcome assessments Chronic kidney disease clearance coronavirus disease COVID-19 decrease dose dose reduction Effect eliminated evaluated exhibited geometric geometric mean ratio glomerular filtration rate group increased risk kidney laboratory measurements Mild mild in severity moderate Nirmatrelvir oral participant Patient patients with moderate pharmacokinetics Phase I plasma plasma concentration positively correlated progression reducing renal renal function renal impairment risk Ritonavir severe disease severe renal impairment systemic Tolerability vital signs [DOI] 10.1002/cpt.2688 PMC 바로가기